David McLoone | lifesitenews.com
American biotechnology company Moderna, developer of one of the country’s two mRNA experimental vaccines for COVID-19, has announced plans to create a hybrid vaccine that will target both COVID and influenza, again using its new mRNA technology.
Read More: Moderna CEO announces development of combined COVID-19/flu vaccine